Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models

Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti–PD-L1, PD-1, and CTLA-4 mAbs)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neoplasia
Main Authors: Rios-Doria, Jonathan, Durham, Nicholas, Wetzel, Leslie, Rothstein, Raymond, Chesebrough, Jon, Holoweckyj, Nicholas, Zhao, Wei, Leow, Ching Ching, Hollingsworth, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4674486/
https://ncbi.nlm.nih.gov/pubmed/26408258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2015.08.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados